References
- Prchal J.T., Trockmorton D.W., Carrol A.J., Fuson E.W., Gams R.A., Prchal J.F. A common progenitor for myeloid and lymphoid cells. Nature 1978; 274: 590–591
- Raskind W.H., Tirumali N., Jacobson R., Singer J., Fialkow J. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 1984; 63: 1318–1323
- Adamson J.W., Eschbach J.W. Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q. J. Med. 1989; 73: 1093–1101
- Jacobs A., Janowska-Wieczorek J., Caro A., Bowen D.T., Lewis T. Circulating erythropoietin in pátients with myelodysplastic syndromes. Br. J. Haematol. 1989; 73: 36–39
- Prchal J.F., Adamson J.W., Murphy S., Steinmann L., Fialkow P.J. Polycytemia vera: the in vitro response of normal and abnormal stem cell lines to erythropoietin. J. Clin. Invest. 1978; 61: 1044–1047
- Cynshi O., Satoh K., Higuchi M., Imai N., Kawaguchi T., Hirashima K. Effects of recombinant human erythropoietin on anaemic W/Wv and SI/SId mice. Br. J. Haematol. 1990; 75: 319–324
- McMahon G., Vragas R., Ryan M., Jain A.K., Abels R.I., Perry B., Smith I.L. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718–1722
- Benett J.M., Catovski D., Daniel M.D., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51: 189–199
- Vadhan-Raj S., Keating M., Lemaistre A., Hittelman W.N., Mc Credie K., Trujillo J.M., Broxmeyer H.E., Hennecy C., Gutterman J.U. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N. Eng. J. Med. 1987; 317: 1545–1552
- Bowen D., Culligan D., Jacobs A. The treatment of anaemia in the myelodysplastic syndrome with recombinant human erythropoietin. Br. J. Haematol. 1991; 77: 419–423
- Bessho M., Jinnal I., Matsuda A., Saito M., Kunitake H. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int. J. Cell Cloning 1990; 8: 445–450
- Schouten H.C., Vellenga E., Van Rhenen D.J., De Wolf J.T.M., Coppens P.J.M., Blijham G.H. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 1991; 5: 432–436
- Stein R.S., Abels R.I., Krantz S.B. Pharmacological doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78: 1658–1663
- Van Kamp H., Prinsze-Postema T.C., Kluin P.M., Den Ottolender G.J., Beverstock G.C., Willemze R., Fibbe W.E. Effect of subcutaneously administrated human recombinant erythropoietin on erythropoiesis in patients with myelodysplastia. Br. J. Haematol. 1991; 78: 488–493
- Greenberg P.L. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders. Clin. Haematol. 1986; 15: 973–993
- Dormer P., Schalhorn A., Wilmanns W., Hershko C. Erythroid and myeloid maturation patterns related to progenitor assessment in the myelodysplastic syndromes. Br. J. Haematol. 1987; 67: 61–66
- Koury M.J., Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248: 378–381